Answers are grounded in this paper and cite their sources.
Peritoneal fibrosis (PF) is a major complication that limits the long-term use of peritoneal dialysis. Its core pathological mechanisms include chronic inflammation, mesothelial-mesenchymal transition, and imbalances in extracellular matrix metabolism. Extracellular vesicles (EVs), as key mediators of intercellular communication, have demonstrated unique value in the early diagnosis and therapeutic intervention of PF in recent years. EVs in peritoneal dialysis effluent carry molecular cargo, including aquaporin-1 (AQP1), miR-432-5p, glycoprotein 96 (gp96), and integrin-linked kinase (ILK), that can dynamically reflect the severity of ultrafiltration failure and fibrosis, thereby establishing a framework for a noninvasive liquid biopsy. Functionally, EVs play dual roles in both promoting and inhibiting fibrosis: ILK-rich EVs derived from mesothelial cells activate fibroblasts via the p38 MAPK pathway, whereas EVs derived from mesenchymal stem cells (MSCs) inhibit the mesothelial-to-mesenchymal transition (MMT). Engineered EVs are emerging as a hot topic in translational research. However, EV heterogeneity, insufficient in vivo tracing, and the model-clinical gap remain key bottlenecks. The integration of single-EV analysis, peritoneal organoids, and AI-driven multi-omics approaches is expected to drive a paradigm shift from “populations of vesicles” to “spatiotemporal functions of individual vesicles.”
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: